Carbylan Therapeutics Inc., of Palo Alto, Calif., said unforeseen delays in connection with the transfer of its drug manufacturing processes to two contract manufacturers delayed the timetable for the second phase III trial, COR1.2, of its Hydros-TA candidate, which is now expected to begin enrolling patients early next year.